Figure 1From: A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitusFluorescence-activated cell sorting analysis of umbilical cord mesenchymal stem cells. Percentages of all CD105, CD73 and CD44 were higher than 95%, while none of CD34, CD45, CD31, CD146 and HLA-DR’s percentage was higher than 1%. WJ-MSCs, Wharton’s Jelly mesenchymal stem cells.Back to article page